Evidence map›Paper›PMID 38936979›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

Chronic Administration of Cannabinoid Agonists ACEA, AM1241, and CP55,940 Induce Sex-Specific Differences in Tolerance and Sex Hormone Changes in a Chemotherapy-Induced Peripheral Neuropathy.

Robert C Barnes, Henry Blanton, Canice Lei Dancel, Isabel Castro-Piedras, Boyd R Rorabaugh, Daniel J Morgan, Josée Guindon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Cannabinoid CBBritish journal of pharmacology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Robert C BarnesDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.
Henry BlantonDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.
Canice Lei DancelDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.
Isabel Castro-PiedrasDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.
Boyd R RorabaughDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.ORCID 0000-0002-5217-8236
Daniel J MorganDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia.
Josée GuindonDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas (R.C.B., H.B., C.L.D., I.C.-P., J.G.); and Departments of Pharmaceutical Sciences (B.R.R.) and Biomedical Sciences (D.J.M.), Marshall University, Huntington, West Virginia josee.guindon@ttuhsc.edu.ORCID 0000-0002-2186-1745

Funding

Mechanisms of cannabinoid toleranceR01DA044999 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GUINDON, JOSEE, MORGAN, DANIEL J · 2018 to 2022
$2.4M
NIDA NIH HHS R01 DA044999
6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy treatment, routinely manifesting as increased pain sensitivity (allodynia) in distal extremities. Despite its prevalence, effective treatment options are limited. Cannabinoids are increasingly being evaluated for their ability to treat chronic pain conditions, including CIPN. While previous studies have revealed sex differences in cannabinoid-mediated antinociception in acute and chronic pain models, there is a paucity of studies addressing potential sex differences in the response of CIPN to cannabinoid treatment. Therefore, we evaluated the long-term antiallodynic efficacy of cannabinoid receptor type 1 (CB

Indexed as

Cannabinoid Receptor AgonistsCannabinoidsDrug TolerancePeripheral Nervous System DiseasesSex CharacteristicsAnimalsAntineoplastic AgentsCisplatinCyclohexanolsFemaleGonadal Steroid HormonesMaleMiceMice, Inbred C57BLReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB23-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolAM 1241Antineoplastic AgentsCannabinoid Receptor AgonistsCannabinoidsCisplatinCyclohexanolsGonadal Steroid HormonesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID38936979
PMCPMC11493449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.